<DOC>
	<DOCNO>NCT01593215</DOCNO>
	<brief_summary>The investigator recently discover genetic variant adrenergic receptor lead increase risk type 2 diabetes . The investigator also see blocker receptor improves impaired insulin secretion animal . The investigator test blocker patient type 2 diabetes without risk variant effort make diabetes treatment individualize .</brief_summary>
	<brief_title>Randomized Study Yohimbine Treatment Type 2 Diabetes Patients Carrying Specific Genetic Risk Variant</brief_title>
	<detailed_description>We recently discover genetic variant adrenergic receptor lead increase risk type 2 diabetes . We also see blocker receptor improves impaired insulin secretion animal . We test blocker patient type 2 diabetes without risk variant effort make diabetes treatment individualize . Patients receive two different dos blocker effect measure oral glucose tolerance test . The study randomize placebo-controlled study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>type 2 diabetes informed consent age 1870 , females postmenopausal heart disease anxiety disorder antidiabetic treatment metformin adrenergic blocker ulcus allergy component capsule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>genetics</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>insulin secretion</keyword>
</DOC>